Vivo Capital’s 10x Genomics TXG Stock Holding History

Vivo Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,798	Closed	-$2.15M	–	63
2021 Q3	$2.15M	Hold	14,798	–	–	0.1%	56
2021 Q2	$2.9M	Hold	14,798	–	–	0.13%	54
2021 Q1	$2.68M	Sell	14,798 -44,179	-75%	-$7.63M	0.09%	57
2020 Q4	$8.35M	Buy	+58,977	New	+$8.56M	0.37%	45

Other funds holding TXG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vivo Capital's TXG Position: Q4 2021 in Review

Vivo Capital sold out of 10x Genomics (TXG) in Q4 2021, closing a stake of 14,798 shares — an estimated $2.15M sold.

Vivo Capital first reported a position in TXG in Q4 2020 and held it in 4 quarters. The position peaked at $8.35M in Q4 2020. 365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

Vivo Capital reported no remaining 10x Genomics position as of Q4 2021 after selling out during the quarter.
Vivo Capital sold 14,798 10x Genomics shares in Q4 2021, an estimated $2.15M.
Vivo Capital first reported a position in 10x Genomics in Q4 2020 and held it in 4 quarters.
Vivo Capital's 10x Genomics position peaked at $8.35M in Q4 2020.
365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on Vivo Capital's 13F filing for Q4 2021, filed 11 Feb 2022.